Trial
NCT02603172
A Safety Study of GSK3039294 in Healthy Volunteers and Patients With Systemic Amyloidosis
Phase ITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
GlaxoSmithKline
Collaborators
—
Condition
Amyloidosis
Intervention
GSK3039294
Why stopped
A new study will be initiated in order to specifically investigate cardiac safety
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2019-09-23